Now I have enough to give a thorough, clinically structured answer. Let me synthesize everything.
Clinical Summary from the Notes
Patient: DVCAD, angioplasty to LCx 1 month ago (stent likely DES), now presenting 19/7 with:
| Parameter | Value | Interpretation |
|---|
| BP | 66/40 mmHg | Haemodynamic shock |
| PR | 62 bpm | Bradycardic / not compensating |
| SpO2 | 92% on RA | Hypoxic |
| CBG | 128 mg/dL | |
| Hb | 5.9 g/dL | Severe anaemia |
| TLC | 19,700 | Leukocytosis |
| Platelets | 25,000 | Severe thrombocytopenia |
| Urea/Cr | 64 / 2.4 | Acute kidney injury |
| AST/ALT | 137 / 49 | Hepatitis |
| Amylase/Lipase | 184 / 119 | Pancreatitis involvement |
| Na/K | 133 / 4.8 | Mild hyponatraemia |
| ECG | RBBB pattern V1, negative axis, non-specific ST changes, deep S in lead II | |
Active problem: Rectal bleeding (P/R) on straining since today - this is a life-threatening GI bleed given Hb 5.9 and haemodynamic shock. The cardiologist's note on the sheet already says: "Cardio opinion - advised to skip antiplatelets, high risk, go for stent (tomorrow)" - which is specifically about holding antiplatelets in this context.
Should You Restart Aspirin and Atorvastatin?
Aspirin (Antiplatelet) - HOLD FOR NOW, Restart Urgently Once Bleeding Controlled
This patient has a life-threatening GI bleed (Hb drop, hemodynamic shock, active PR bleeding) at only 1 month post-PCI to LCx - this is the highest-risk window for stent thrombosis. You are caught between two catastrophes:
Risk of stopping DAPT: Drug-eluting stents (DES) have the highest thrombosis risk in the first 30 days. At 1 month post-PCI, stent thrombosis risk from DAPT interruption is significant and carries ~40-60% mortality.
Risk of continuing DAPT: The patient is in hemorrhagic shock (BP 66/40), Hb 5.9, Plt 25k - continuing antiplatelets will likely cause fatal hemorrhage.
The ESC/ACG framework for life-threatening GI bleed on DAPT:
- Discontinue DAPT (both aspirin + P2Y12) - already done per the cardiologist note
- Aggressive resuscitation, transfuse PRBCs (1U already given - likely needs more given Hb 5.9 and shock)
- Urgent endoscopy (EGD/colonoscopy) to confirm hemostasis
- Restart aspirin on the day hemostasis is endoscopically confirmed - ACG guidelines specifically state aspirin should NOT be held indefinitely and should be resumed the day endoscopic hemostasis is confirmed
- If DAPT is restarted, add high-dose PPI indefinitely
- Thrombocytopenia (Plt 25k) is a separate, complicating factor - antiplatelets should not be restarted until haematology clears the platelet count (currently haematology referral is noted)
The cardiologist's note says "skip antiplatelets" - this is appropriate for the acute hemorrhage phase only. The goal is to bridge safely to hemostasis and restart as soon as possible.
Atorvastatin - DO NOT STOP
Atorvastatin is
not contributing to the bleeding and has cardioprotective and plaque-stabilizing effects critical post-PCI. The
2024 ACC/AHA perioperative guidelines explicitly state statins should be continued perioperatively and not interrupted even when aspirin is held.
- Continue atorvastatin at the dose already prescribed (typically 40-80mg for post-ACS/PCI)
- Note: AST/ALT are mildly elevated (137/49) - monitor LFTs, but this is likely from the hemodynamic shock/hypoperfusion, not statin hepatotoxicity. If LFTs worsen significantly (>3x ULN), reconsider, but do not stop empirically now.
Immediate Management Priorities
1. Resuscitate First (This is the Immediate Priority)
- IV access x2, aggressive IV fluids (cautious given cardiac history - use crystalloid boluses)
- More PRBCs - Hb 5.9 with hemodynamic shock: target Hb >8-9g/dL in this CAD patient; already received 1U, needs more
- Platelet transfusion - Plt 25k is critically low; threshold for transfusion in active bleeding is typically <50k; haematology referral already done - get platelets urgently
- Fresh Frozen Plasma (FFP) - APTT 24:2 is borderline; if coagulopathy worsens, consider
- Correct hypoxia - SpO2 92%, supplement oxygen (nasal cannula or mask), target SpO2 >95%
2. Identify the Bleeding Source
- P/R bleeding with constipation and straining - likely lower GI (haemorrhoids, anal fissure given straining) but cannot rule out upper GI source with melaena presentation
- Urgent colonoscopy / proctoscopy once haemodynamically stabilised
- If upper GI source suspected, urgent EGD
- Hb drop from what level is not documented - but Hb 5.9 with shock suggests significant blood loss
3. Address the Thrombocytopenia (Plt 25k)
This is not aspirin-related thrombocytopenia at Plt 25k. Possible causes in this patient:
- History of malaria (confirmed by the notes) - malaria-associated thrombocytopenia is very common and can be severe
- Drug-induced (check all medications)
- Disseminated intravascular coagulation (DIC) - check fibrinogen, D-dimer
- TTP/HUS (given AKI, elevated LFTs, thrombocytopenia - this triad warrants consideration)
- Haematology to sort this out urgently
4. Regarding the Angioplasty and Stent
- The cardiologist note mentions "go for stent tomorrow" - this likely refers to stenting an additional lesion (DVCAD = 2-vessel disease; only LCx was stented 1 month ago, second vessel may still need intervention)
- Any further procedure is contraindicated today given Hb 5.9, Plt 25k, and active bleeding/shock
- This elective/staged procedure must be deferred until the patient is stabilised, bleeding stopped, and platelets are correctable
5. ECG Changes
- RBBB pattern + negative axis + non-specific ST changes: monitor closely
- Rule out right heart strain (PE is in the differential given the thrombocytopenia and systemic illness), or demand ischemia from the acute anemia and hypotension
- Serial ECGs, troponin
6. Liver/Pancreas Findings
- Elevated amylase (184) and lipase (119) with elevated transaminases - could represent ischemic hepatitis/pancreatopathy from hypoperfusion (BP 66/40)
- Monitor trend; keep NBM if pancreatitis is significant
7. Renal Function (Cr 2.4)
- Likely pre-renal AKI from the shock state
- Aggressive fluid resuscitation, monitor urine output
- Avoid NSAIDs (contraindicated anyway)
- Adjust drug doses accordingly
8. Medications to Start/Continue
| Drug | Action | Reason |
|---|
| Aspirin | HOLD - restart day hemostasis confirmed endoscopically | Life-threatening GI bleed |
| Clopidogrel/P2Y12 | HOLD - restart when platelet count safe and hemostasis confirmed | Life-threatening GI bleed + Plt 25k |
| Atorvastatin | CONTINUE | Cardioprotective; not causing bleeding |
| High-dose PPI (pantoprazole 40mg BD IV) | START NOW | Mandatory in all GI bleed on antiplatelets; mucosal protection for restart |
| Beta-blocker (if on one) | CONTINUE | Perioperative cardiac protection |
| Oxygen supplementation | START | SpO2 92% |
| IV fluids | START | Hemodynamic resuscitation |
| PRBCs | Continue transfusing | Target Hb >8-9 |
| Platelets | Transfuse - coordinate with haematology | Active bleeding + Plt 25k |
Summary in One Line
Hold aspirin and P2Y12 inhibitor now (as the cardiologist has already advised), continue atorvastatin, resuscitate aggressively, correct the critical thrombocytopenia via haematology, identify and control the bleeding source endoscopically, then restart aspirin on the same day endoscopic hemostasis is confirmed - ideally within days, not weeks, given the 1-month post-PCI window.
Important: This patient is critically unwell and the management decisions - particularly around restarting antiplatelets in a post-stent patient with active severe GI hemorrhage and severe thrombocytopenia - require urgent multidisciplinary input: cardiology, gastroenterology, haematology, and critical care. The notes already show this team approach is being initiated. Atorvastatin should never be stopped in a post-PCI patient during an acute event.
References: Mulholland and Greenfield's Surgery 7e (Algorithm 14.2 - Antiplatelet Management after PCI); ESC/ACG GI Bleed on DAPT framework; 2025 ACC/AHA ACS Guideline